The open label studies are helpful, they add to totality of data and broaden safety database. Conducting them was better than giving drug away with no protocol. It allowed us to collect information. The NIAID study is the key though. This isn' a home run drug, but appears active.

— Scott Gottlieb, MD (@ScottGottliebMD) April 29, 2020